Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Validation of the CNS-IPI-C Prognostic Model in Patients with Systemic DLBCL in the Real World

Michal Masar, Prokop Vodicka, Samuel Hricko, Andrea Janikova, Katerina Benesova, David Salek, Jana Salkova, Martina Filipova, Jan Galko, Vit Campr, Magdalena Klanova, Marek Trneny

Blood (2024) 144 (Supplement 1): 3081.

https://doi.org/10.1182/blood-2024-208592

Published: 2024

Journal Articles

BMI and Its Changes As a Predictor of Survival in DLBCL Patients

Michal Masar, Prokop Vodicka, Magdalena Klanova, Kamila Polgarova, Katerina Benesova, Diana Malarikova, Jana Salkova, Jan Koren, Pavel Klener, Marek Trneny

Blood (2024) 144 (Supplement 1): 1713.

https://doi.org/10.1182/blood-2024-208542

Published: 2024

Journal Articles

biomarker Driven Strategies for Targeted Elimination of Hypoxia Adapted Lymphoma Cells

Pavel Klener, Jr., Lenka Daumová, Dmitry Kazantsev, Ladislav Anděra, Jiří Petrák, Alexandra Dolníková, Nardjas Bettazová, Petra Kovaříková, Nicol Renešová, Liliana Tušková, Dana Sovilj, Marek Trněný, Magdalena Klanova, Ondrej Havránek

Blood (2023) 142 (Supplement 1): 4374.

https://doi.org/10.1182/blood-2023-182705

Published: 2023

Journal Articles

Single Cell RNA Sequencing Enables Identification of Mantle Cell Lymphoma Subclones with Drug-Resistant Profiles Already at Diagnosis and May be Used for Therapy Prognostication and Personalization

Dmitry Kazantsev, Magdalena Klanova, Michal Kolář, Robert Ivánek, Marek Trněný, Pavel Klener, Jr.

Blood (2023) 142 (Supplement 1): 3004.

https://doi.org/10.1182/blood-2023-185925

Published: 2023

Journal Articles

Risk of Central Nervous System Vs. Systemic Relapse in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: What Should We Focus on?

Magdalena Klanova, Samuel Hricko, Michal Masar, David Salek, Prokop Vodicka, Natasa Kopalova, Petra Blahovcova, Katerina Benesova, Jozef Michalka, Jan Koren, Andrea Janikova, Marek Trneny

Blood (2023) 142 (Supplement 1): 4479.

https://doi.org/10.1182/blood-2023-178208

Published: 2023

Journal Articles

Do the Control Cohorts of Phase III Randomized Trials Reflect the Real-World Results of DLBCL Patients?

Prokop Vodicka, Andrea Janikova, David Belada, Heidi Mocikova, Vit Prochazka, Juraj Duras, Katerina Steinerova, Vit Campr, Katerina Benesova, Samuel Hricko, Alice Sykorova, Petra Blahovcova, Radek Jaksa, Magdalena Klanova, Marek Trněný

Blood (2023) 142 (Supplement 1): 4485.

https://doi.org/10.1182/blood-2023-185620

Published: 2023

Journal Articles

DLBCL Patients' Journey: From Symptoms to Diagnosis

Prokop Vodicka, Michal Masar, Magdalena Klanova, Katerina Benesova, Jan Koren, Pavel Klener, Petra Blahovcova, Sarka Hrabetova, Jitka Dlouha, Marek Trněný

Blood (2023) 142 (Supplement 1): 3140.

https://doi.org/10.1182/blood-2023-186207

Published: 2023

Journal Articles

Diagnosis to Treatment Interval Is the Most Significant Prognostic Factor Compared to Symptoms to Treatment As Well As to Contact to Treatment Intervals in DLBCL Patients

Prokop Vodicka, Michal Masar, Magdalena Klanova, Katerina Benesova, Jan Koren, Pavel Klener, Petra Blahovcova, Jitka Dlouha, Sarka Hrabetova, Marek Trněný

Blood (2023) 142 (Supplement 1): 4510.

https://doi.org/10.1182/blood-2023-186467

Published: 2023

Journal Articles

Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib Synergizes with BH3-Mimetics in Experimental Models of Relapsed/Refractory Mantle Cell Lymphoma

Diana Malarikova, Radek Jorda, Alexandra Dolníková, Ondrej Havranek, Eva Pokorna, Dmitry Kazantsev, Dana Sovilj, Karel Helman, Magdalena Klanova, Ladislav Andera, Miroslav Strnad, David Chiron, Marek Trneny, Pavel Klener, Jr.

Blood (2022) 140 (Supplement 1): 5996–5997.

https://doi.org/10.1182/blood-2022-168617

Published: 2022

Journal Articles

Sequencing-Based Analysis of Clonal Evolution of 25 Mantle Cell Lymphoma Patients at Diagnosis and after Failure of Standard Immunochemotherapy

Jana Karolova, Dmitry Kazantsev, Michael Svaton, Liliana Tušková, Kristina Forsterova, Diana Malarikova, Katerina Benesova, Tomáš Heizer, Alexandra Dolníková, Magdalena Klanova, Eva Fronkova, Marek Trněný, Pavel Klener, Jr.

Blood (2022) 140 (Supplement 1): 6409–6410.

https://doi.org/10.1182/blood-2022-166069

Published: 2022

Journal Articles

High-Dose Methotrexate Is Not Associated with Reduction in CNS Relapse in Patients with Aggressive B-Cell Lymphoma: An International Retrospective Study of 2300 High-Risk Patients

Katharine Louise Lewis, Lasse H. Jakobsen, Diego Villa, Sabela Bobillo, Karin Ekstroem Smedby, Kerry J. Savage, Toby A. Eyre, Kate Cwynarski, Paris L Caporn, Joan Van Zyl, Magdalena Klanova, Marek Trněný, Robert Puckrin, Douglas A. Stewart, Mark J Bishton, Christopher P. Fox, Aung M Tun, Gita Thanarajasingam, Faouzi Djebbari, Erel Joffe, Sandra Eloranta, Sara Harrysson, Laurie H. Sehn, Seth M Maliske, Kittika Poonsombudlert, Xiao Guo, Greg Hapgood, Kate Manos, Eliza Hawkes, Jahanzaib Khwaja, Adrian Minson, Michael Dickinson, Andreas Kiesbye Øvlisen, Gareth P Gregory, Michael Gilbertson, Isaac T Streit, Hamish W Scott, Matthew Ku, Sanjay de Mel, Kar Ying Yong, Liu Xin, Mridula Mokoonlall, Dipti Talaulikar, Nicholas L McVilly, Anna Johnston, Matthew J Brunner, Priyanka A Pophali, Matthew J. Maurer, Tarec Christoffer El-Galaly, Chan Yoon Cheah

Blood (2021) 138 (Supplement 1): 181.

https://doi.org/10.1182/blood-2021-146737

Published: 2021

Journal Articles

Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib Synergizes with BCL2 Inhibitor Venetoclax in Experimental Models of Chemotherapy Refractory Mantle Cell Lymphoma

Diana Malarikova, Radek Jorda, Alexandra Dolnikova, Eva Pokorna, Dmitry Kazantsev, Ondrej Havranek, Karel Helman, Magdalena Klanova, Miroslav Strnad, Marek Trneny, Pavel Klener, Jr.

Blood (2021) 138 (Supplement 1): 1203.

https://doi.org/10.1182/blood-2021-150517

Published: 2021

Journal Articles

A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: The First-Mind Trial

John M Burke, MD, Marc André, Bruce D. Cheson, MD, Johannes Duell, MD, Grzegorz Nowakowski, MD, Andreas Rosenwald, MD, Gilles A. Salles, MD PhD, Jeff P. Sharman, MD, Philipp Bernhard Staber, MD PhD, Marek Trněný, MD, Jason R. Westin, MD, Wolfram Brugger, Günter Fingerle-Rowson, MD PhD, Magdalena Klanova, Guido Würth, PhD, Lorenz Truemper, MD

Blood (2019) 134 (Supplement_1): 2877.

https://doi.org/10.1182/blood-2019-128021

Published: 2019

Journal Articles

Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL

Magdalena Klanova, Laurie H. Sehn, Isabelle Bence-Bruckler, Federica Cavallo, Jie Jin, Maurizio Martelli, Douglas Stewart, Umberto Vitolo, Francesco Zaja, Qingyuan Zhang, Federico Mattiello, Gila Sellam, Elizabeth A. Punnoose, Edith Szafer-Glusman, Christopher R. Bolen, Mikkel Z. Oestergaard, Guenter R. Fingerle-Rowson, Tina Nielsen, Marek Trneny

Blood (2019) 133 (9): 919–926.

https://doi.org/10.1182/blood-2018-07-862862

Published: 2019

Includes: Supplemental data

Journal Articles

Co-Targeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Refractory Mantle Cell Lymphoma with Complex Karyotype Changes

Pavel Klener, Jr., Marek Trněný, Ladislav Andera, MSc, PhD, Zuzana Nahacka, MSc, Magdalena Klanova, MD PhD, Jana Karolova, MD, Michael Svaton, MD, Ondrej Havranek, MDPhD, Jan Soukup, MD, Zuzana Zemanova, PhD, Diana Tuskova, MD, Eva Pokorna, Kristina Forsterova, MSc, PhD, Petra Vockova, MD, Eva Fronkova, MD PhD, Dana Prukova, Ing, PhD

Blood (2018) 132 (Supplement 1): 42.

https://doi.org/10.1182/blood-2018-99-112437

Published: 2018

Journal Articles

Role of Angiogenesis and Anti-Angiogenic Treatment Strategies in Mantle Cell Lymphoma

Petra Vockova, MD, Magdalena Klanova, MD PhD, Jan Molinsky, MD PhD, Diana Tuskova, MD, Bokang Calvin Maswabi, MD PhD, Radek Jaksa, MD, Marek Trneny, MD CSc, Pavel Klener, Jr.

Blood (2018) 132 (Supplement 1): 1672.

https://doi.org/10.1182/blood-2018-99-116874

Published: 2018

Journal Articles

Low Peripheral Blood NK Cell Count Is Associated with Worse Clinical Outcome in Patients with Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Immunochemotherapy: Results from the Frontline Phase 3 GALLIUM and GOYA Trials

Magdalena Klanova, MD, Mikkel Z. Oestergaard, Marek Trněný, MD PhD, Wolfgang Hiddemann, MD PhD, Robert Marcus, Laurie H. Sehn, MDMPH, Umberto Vitolo, MD, Alexandra Bazeos, Valentin Goede, MD, Harald Zeuner, Andrea Knapp, Denis Sahin, Nathalie Danesi, Christopher Bolen, Susan Robson, Jeffrey M. Venstrom, Tina Nielsen, Günter Fingerle-Rowson

Blood (2017) 130 (Supplement 1): 727.

https://doi.org/10.1182/blood.V130.Suppl_1.727.727

Published: 2017

Journal Articles

Systematic Analysis of the Prognostic Impact of Somatic Mutations in Diffuse Large B-Cell Lymphoma (DLBCL) with Evaluation of Cell-of-Origin Dependence: Results from the Phase 3 GOYA Trial in Previously Untreated DLBCL

Christopher Bolen, Magdalena Klanova, MD, Marek Trněný, MD PhD, Laurie H. Sehn, MDMPH, Umberto Vitolo, MD, Maurizio Martelli, Günter Fingerle-Rowson, Tina Nielsen, Georg Lenz, Mikkel Z. Oestergaard

Blood (2017) 130 (Supplement 1): 2729.

https://doi.org/10.1182/blood.V130.Suppl_1.2729.2729

Published: 2017

Journal Articles

MCL1 Targeting Agent Homoharringtonine Exerts Strong Cytotoxicity Towards Diffuse Large B-Cell Lymphoma (DLBCL) Cells and Synergizes with BCL2 Targeting Agent ABT199 in Eliminating BCL2-Positive DLBCL Cells

Magdalena Klanova, MD, Ladislav Andera, M.Sc. PhD, Jan Soukup, MDPhD, Brazina Jan, M.Sc., Jan Svadlenka, M.Sc., Simona Benesova, M.Sc., Dana Prukova, M.Sc. PhD, Dana Vejmelkova, M.Sc., Radek Jaksa, MD, Karel Helman, PhD, Petra Vockova, MD, Lucie Lateckova, MD, Jan Molinsky, MD PhD, Bokang Maswabi, MD, Mahmudul Alam, PhD, Roman Kodet, Prof. MD, Marek Trneny, Pavel Klener, MD, PhD

Blood (2014) 124 (21): 3645.

https://doi.org/10.1182/blood.V124.21.3645.3645

Published: 2014

Journal Articles

Defining Criteria for Diagnosis of Occult Lymphomatous Involvement in Cerebrospinal Fluid

Heidi Mocikova, MD, PhD, Magdalena Klanova, MD, Martin Spacek, MD, PhD, Robert Pytlik, MD, PhD, Tomas Kozak, MD, PhD, Prof., Marek Trneny, MD, PhD, Prof., Vit Pospisil, PhD

Blood (2014) 124 (21): 5412.

https://doi.org/10.1182/blood.V124.21.5412.5412

Published: 2014

NARROW

Validation of the CNS-IPI-C Prognostic Model in Patients with Systemic DLBCL in the Real World

BMI and Its Changes As a Predictor of Survival in DLBCL Patients

biomarker Driven Strategies for Targeted Elimination of Hypoxia Adapted Lymphoma Cells

Single Cell RNA Sequencing Enables Identification of Mantle Cell Lymphoma Subclones with Drug-Resistant Profiles Already at Diagnosis and May be Used for Therapy Prognostication and Personalization

Risk of Central Nervous System Vs. Systemic Relapse in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: What Should We Focus on?

Do the Control Cohorts of Phase III Randomized Trials Reflect the Real-World Results of DLBCL Patients?

DLBCL Patients' Journey: From Symptoms to Diagnosis

Diagnosis to Treatment Interval Is the Most Significant Prognostic Factor Compared to Symptoms to Treatment As Well As to Contact to Treatment Intervals in DLBCL Patients

Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib Synergizes with BH3-Mimetics in Experimental Models of Relapsed/Refractory Mantle Cell Lymphoma

Sequencing-Based Analysis of Clonal Evolution of 25 Mantle Cell Lymphoma Patients at Diagnosis and after Failure of Standard Immunochemotherapy

High-Dose Methotrexate Is Not Associated with Reduction in CNS Relapse in Patients with Aggressive B-Cell Lymphoma: An International Retrospective Study of 2300 High-Risk Patients

Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib Synergizes with BCL2 Inhibitor Venetoclax in Experimental Models of Chemotherapy Refractory Mantle Cell Lymphoma

A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: The First-Mind Trial

Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL

Co-Targeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Refractory Mantle Cell Lymphoma with Complex Karyotype Changes

Role of Angiogenesis and Anti-Angiogenic Treatment Strategies in Mantle Cell Lymphoma

Low Peripheral Blood NK Cell Count Is Associated with Worse Clinical Outcome in Patients with Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Immunochemotherapy: Results from the Frontline Phase 3 GALLIUM and GOYA Trials

Systematic Analysis of the Prognostic Impact of Somatic Mutations in Diffuse Large B-Cell Lymphoma (DLBCL) with Evaluation of Cell-of-Origin Dependence: Results from the Phase 3 GOYA Trial in Previously Untreated DLBCL

MCL1 Targeting Agent Homoharringtonine Exerts Strong Cytotoxicity Towards Diffuse Large B-Cell Lymphoma (DLBCL) Cells and Synergizes with BCL2 Targeting Agent ABT199 in Eliminating BCL2-Positive DLBCL Cells

Defining Criteria for Diagnosis of Occult Lymphomatous Involvement in Cerebrospinal Fluid

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only